Project Grant R43NS127689
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $296,151 to Insoma Bio, Inc. to investigate the use of their proprietary Fractomer biomaterial to improve outcomes after peripheral nerve repair. The project aims to demonstrate that Fractomer, an injectable polypeptide scaffold, can provide the necessary mechanical support and...
- This Project Grant award of $567,037.00 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to characterize the synchrony between peripheral nerve post-injury activity and brain plasticity. The research will utilize an innovative optical imaging method to simultaneously monitor nerve regeneration and corresponding changes in the cerebral cortex in mice...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $310,834 to Clemson University to develop a nanoparticle-based platform for targeted, non-invasive delivery of therapeutics to the peripheral nervous system. The goal is to improve treatments for peripheral nerve injuries and diseases by overcoming the blood-nerve barrier that...
- This $999,998 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports the development of Renerva LLC's Peripheral Nerve Matrix (PNM) technology. PNM is a tissue-based hydrogel derived from porcine nerve that aims to improve functional outcomes for patients with challenging peripheral nerve gap injuries. The Phase I project will optimize the PNM...
- Renerva LLC, a for-profit manufacturer, is developing peripheral nerve matrix (PNM) technologies to facilitate functional recovery in animal models of direct muscle neurotization (DMN) through a $494,955 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853). The two-year project aims to 1) optimize the formulation of a clinical-grade PNM product to provide...
- This $961,052 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to develop a nanoparticle-encapsulated siRNA formulation targeting the Fidgetin-like 2 (FL2) protein to promote tissue repair and functional recovery after spinal cord injury. The awardee, Microcures Inc., will conduct proof-of-feasibility studies in a rat contusion model to evaluate...
- This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $294,505 to support the development and commercialization of a targeted fluorescence dye for intraoperative imaging and precision surgical treatment of head and neck cancer (HNC). The goal is to create a small peptide-based fluorescent probe that can specifically stain HNC tumors to assist surgeons in identifying tumors...
- This Project Grant award of $1,188,230 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to evaluate the cellular composition, activation state, and spatial niches involved in neuroma formation following severe peripheral nerve injuries. The primary goals are to validate preliminary data indicating that neutrophil extracellular traps (NETs) may be an...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $638,718 project grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to The Feinstein Institutes For Medical Research to conduct research on "Selective, Epineural Stimulation of Peripheral Nerves with Interferential Electrical Fields". The primary objectives are to: 1) Test the hypothesis that interferential current stimulation can selectively activate specific...
- This Project Grant awarded by the National Science Foundation (CFDA 47.041 - Engineering) to Cleveland State University (CSU) provides $500,000 in funding from January 1, 2025 to December 31, 2027 to develop bioprinted tissue scaffolds with Schwann cell density gradients and electrical conductivity for peripheral nerve regeneration. The goal is to understand how Schwann cell density gradients and electrical properties within the scaffolds can enhance the regeneration of injured peripheral...
INTRAOPERATIVE NERVE DAMAGE ASSESSMENT USING NERVE-SPECIFIC FLUORESCENCE GUIDED SURGERY - PROJECT SUMMARY ACUTE PERIPHERAL NERVE CRUSH INJURIES FREQUENTLY RESULT FROM CLOSED OR OPEN FRACTURES, JOINT DISLOCATIONS, AND HIGH- ENERGY COLLISIONS. NERVE CRUSH, STRETCH, OR TRANSECTION CAN LEAD TO FUNCTIONAL DEFICITS RANGING FROM NUMBNESS TO COMPLETE MOTOR AND SENSORY FUNCTION LOSS, AFFECTING ~1.6M TRAUMA PATIENTS ANNUALLY. ASSESSMENT OF THE DEGREE OF INJURY AND THE POSSIBILITY FOR FUNCTIONAL RECOVERY AFTER INJURY REMAINS CHALLENGING AND INTRAOPERATIVE NERVE STIMULATION, THE ONLY METHODOLOGY TO AID IN DECISION-MAKING DURING NERVE REPAIR SURGERY, OFTEN YIELDS MINIMALLY USEFUL INFORMATION. THUS, SURGEONS ARE LEFT TO MAKE NERVE DAMAGE ASSESSMENTS VIA GROSS VISUAL EXAMINATION, WHICH FAILS TO CAPTURE THE DEGREE OF AXONAL DISRUPTION, LEAVING ~50% OF PATIENTS WITH POOR FUNCTIONAL RECOVERY OUTCOMES. SURGEONS AND PATIENTS WOULD BENEFIT FROM A RAPID INTRAOPERATIVE ASSESSMENT OF NERVE DAMAGE TO MAKE INFORMED TREATMENT DECISIONS. WE HYPOTHESIZE THAT FLUORESCENCE IMAGING USING A NOVEL NERVE- SPECIFIC FLUOROPHORE COULD PROVIDE AN OBJECTIVE METHODOLOGY TO DETERMINE THE DEGREE AND RECOVERABILITY OF NERVE INJURY, GUIDING SURGICAL INTERVENTION IN REAL-TIME TO IMPROVE PATIENT OUTCOMES FOLLOWING ORTHOPAEDIC TRAUMA SURGERY. WE HAVE DEVELOPED A LIBRARY OF FIRST-IN-KIND, TARGETED, NEAR-INFRARED (NIR) FLUOROPHORES THAT LABEL NERVE TISSUE WITH HIGH AFFINITY AND ARE CURRENTLY UNDERGOING PRECLINICAL PHARMACOLOGY AND TOXICOLOGY TESTING TO FACILITATE FIRST-IN-HUMAN (FIH) TRIALS FOR IMPROVED INTRAOPERATIVE NERVE VISUALIZATION. THESE FLUOROPHORES PROVIDE NERVE VISUALIZATION WITH HIGH CONTRAST AT MILLIMETER TO CENTIMETER TISSUE DEPTHS IN MICE, RATS, AND SWINE AND PRELIMINARY STUDIES SHOW CLEAR IDENTIFICATION BETWEEN HEALTHY AND INJURED NERVE TISSUES FOLLOWING TOPICAL OR SYSTEMIC ADMINISTRATION. HEREIN, WE PROPOSE TO FULLY CHARACTERIZE THE FLUORESCENT UPTAKE PROFILES AND INTENSITY DIFFERENCES BETWEEN HEALTHY AND DAMAGED NERVE TISSUE USING OUR NIR NERVE-SPECIFIC FLUOROPHORES TO PROVIDE AN OBJECTIVE METHODOLOGY FOR INTRAOPERATIVE NERVE DAMAGE ASSESSMENT. THIS STUDY'S IMMEDIATE MILESTONES WILL INCLUDE (1) SELECTION OF AN ADMINISTRATION TIME POINT FOR THE DEVELOPED METHODOLOGY, (2) QUANTIFICATION OF FLUORESCENCE INTENSITY (FI) AND UPTAKE PARAMETERS IN HEALTHY, PERMANENTLY DAMAGED, AND RECOVERING NERVE TISSUE IN MOUSE SCIATIC NERVE INJURY MODELS AND (3) VALIDATION OF THE DEVELOPED NERVE DAMAGE ASSESSMENT METHODOLOGY IN A BLINDED RAT SCIATIC NERVE INJURY STUDY FOR FUTURE CLINICAL TRANSLATION. COMPLETION OF THE PROPOSED AIMS WILL RESULT IN THE FIRST OBJECTIVE NERVE DAMAGE ASSESSMENT METHODOLOGY FOR TRAUMA SURGERY UTILIZING NOVEL NIR NERVE-SPECIFIC FLUOROPHORES DEVELOPED BY INHERENT TARGETING. THE PROPOSED STUDIES WILL PROVIDE PROOF-OF-CONCEPT FOR THE EXPANDED UTILITY OF OUR NOVEL PROBE FOR FUTURE CLINICAL TRANSLATION, ENABLING A ROBUST DIAGNOSTIC ASSESSMENT FOR PATIENTS. THIS WORK WILL BUILD UPON WORK UNDERWAY TO OBTAIN CLINICAL APPROVAL FOR THESE NOVEL NERVE-SPECIFIC PROBES AND PROVIDE A STRONG FOUNDATION AS A PLATFORM TECHNOLOGY FOR INTRAOPERATIVE GUIDANCE. IN PHASE II OF THIS PROJECT, FIH TRIALS WILL BE COMPLETED FOR THE DEVELOPED NERVE DAMAGE ASSESSMENT METHODOLOGY TO VALIDATE TRANSLATION TO TRAUMA PATIENTS UNDERGOING REPARATIVE SURGERY.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 12/9/24 | ||
| Not listed | $0 | 11/24/22 | ||
| Not listed | $375.1k | 9/22/22 | ||
| Not listed | $375.1k | 9/22/22 |